Compare Biogen Inc (BIIB) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Walmart Stores Inc — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while Walmart Stores Inc trades at $113.88 (market cap $904.83B). The key difference: Walmart Stores Inc is far larger — about 31.9× Biogen Inc's market cap, and Walmart Stores Inc pays a 0.87% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | WMT | |
|---|---|---|
Market Cap | $28.34B | $904.83B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $134.20 |
52-Week Low | $122.68 | $95.05 |
Enterprise Value | $30.62B | $968.28B |
Volume | — | 5,675,288 |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Walmart (WMT) trades at $114.78, up 0.77% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong revenue growth to $681.0B in 2025 and a rising net income margin of 2.85%. Analyst consensus is strongly bullish with a $142.10 price target, though technical indicators show resistance near $115. Recent news highlights operational expansions in drone delivery and AI tools, alongside competitive pressures as Amazon overtakes it on the Fortune 500.
The outlook for WMT is positive based on fundamental strength and analyst optimism, but near-term technical resistance and competitive risks warrant caution. Investment opportunity lies in its consistent earnings performance and dividend yield, while risks include market volatility and execution challenges in e-commerce growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
